Demonstrating how to verify CAR-T cell function in microfluidic picodroplets

In recent years, cell therapy has gained significant attention as a method for utilizing the immune system in the fight against tumors. This is achieved through the reprogramming of T-cells collected from patients to create personalized medicines.

T-cell therapy leverages the body's innate ability to identify and eliminate tumor cells, which can become lost or overpowered as cancer progresses. Extracting and modifying a patient's T-cells makes it possible to restore the ability to attack cancer cells.

For the effective and efficient development of these therapies, rapid and accurate assays are necessary to assess the potency of the modified T-cells against the target tumor.

This article introduces a novel picodroplet-based method for validating the functionality of CAR-T cells. This user-friendly and robust approach combines the advantages of Sphere Fluidics' high-throughput picodroplet technology with a granzyme B assay to study cell-mediated cytotoxicity (as shown in Figure 1).

The engineered T-cells and target cells are co-encapsulated within picoliter-volume droplets in an oil emulsion, along with granzyme B substrate.

The release of Granzyme B by the T-cell, which serves as an indicator of the cell's ability to recognize and eliminate the cancer cell, can be monitored to assess its potential anti-cancer activity.

This method allows for rapid cell product efficacy assessments, thereby streamlining the quality control release process of the cell product.

Demonstrating how to verify CAR-T cell function in microfluidic picodroplets

Figure 1. Workflow depicting high throughput CAR-T cell function verification in microfluidic picodroplets. Image Credit: Sphere Fluidics

About picodroplet technology

The development of picodroplet-based technology has positioned it as a highly appealing microfluidic technique for single-cell functional analysis. This method offers several benefits compared to conventional tools.

Picodroplets offer a distinct microenvironment for high-throughput analysis of cell secretion and cell-cell interaction studies at the single-cell level.

The miniaturization of the picoliter volumes results in faster mixing and reduced sample dilution, thereby increasing detection sensitivity and minimizing sample requirements and reaction times.

About Granzyme B detection in picodroplets

The detection of Granzyme B release in picodroplets is achieved through the use of the commercially available SensoLyte® Granzyme B Activity Assay Kit, developed by Anaspec in Fremont, CA. This assay has been adapted for use in picodroplets.

The assay operates on the principle of cleavage of a Granzyme B substrate peptide labeled with a 5-FAM fluorophore and a QXL®-520 fluorophore quencher. In the absence of cleavage, no fluorescence is emitted due to the quenching effect of the adjacent QXL®-520 molecule (as illustrated in Figure 2A).

In the presence of Granzyme B, the substrate peptide is cleaved, releasing the quenching molecule and resulting in a fluorescent signal (as shown in Figures 2A and B).

Demonstrating how to verify CAR-T cell function in microfluidic picodroplets

Figure 2. Principle of Granzyme B detection assay. A) Granzyme B substrate peptide labelled with 5-FAM (green star) and a QXL®-520 fluorophore quencher (grey star). No fluorescence is detected on excitation due to Fluorescence Resonance Energy Transfer (FRET) from 5-FAM to QXL®-520 (left side). On cleavage with Granzyme B the quenching molecule is removed, and fluorescence is emitted from 5-FAM (right side). B) Application of Granzyme B activity assay to CAR-T cell/target cell interaction. Left: CAR-T cell and nontarget cell, no CAR mediated signal, no Granzyme B release, 5-FAM fluorescence quenched. Right: CAR-T cell interaction with target cell results in CAR mediated signal, Granzyme B release, substrate peptide cleavage, release of the quencher and fluorescence is then detected. Image Credit: Sphere Fluidics

Granzyme B detection in picodroplets

To verify the general feasibility of the assay, two populations of picodroplets of approximately 450 pL volume were generated using the Picodroplet Single Cell Encapsulation System.

One population only consisted of the fluorogenic Granzyme B substrate peptide (serving as a negative control), while the other population co-encapsulated recombinant Granzyme B and the substrate peptide. Figure 3 illustrates micrographs of the two populations in brightfield (left) and green fluorescence (right) after a 2-hour incubation at 37 °C.

Only picodroplets that contained both Granzyme B and the substrate peptide (bottom) exhibited detectable fluorescence after the 2-hour incubation, while picodroplets containing only the substrate peptide (top) displayed low to no background fluorescence.

Demonstrating how to verify CAR-T cell function in microfluidic picodroplets

Figure 3. Detection of Granzyme B activity in picodroplets using a fluorogenic 5-FAM/ QXL®-520 substrate peptide. Brightfield (left side) and Fluorescence micrographs (right side) 2h post generation. Scale bar: 100 μm. Image Credit: Sphere Fluidics

Granzyme B detection assay with T cells and target cells

In the next step, researchers co-encapsulated polyclonal human donor T cells genetically modified to express a Chimeric Antigen Receptor (CAR) directed against Prostate-Specific Membrane Antigen (PSMA) with target cells expressing PSMA (PC3-LN3-PSMA) and the fluorogenic Granzyme B substrate peptide.

The researchers employed a custom-made biochip with two separate aqueous inlets to keep the CAR T and target cells apart until immediately before encapsulation. The cell concentrations were adjusted so that only 20% of the picodroplets contained a CAR T cell, with over 75% of the picodroplets receiving at least one target cell.

Approximately 15% (0.75 x 0.2) generated picodroplets contained at least one CAR-T cell and one target cell, meaning that 150,000 of the 1 million picodroplets had both a CAR-T cell and a target cell.

As a control, the researchers co-encapsulated the CAR T cells with PC3-LN3 cells lacking PSMA expression, along with the fluorogenic peptide substrate, under otherwise identical conditions.

The picodroplets were collected in an Eppendorf tube and observed under a fluorescence microscope for Granzyme B activity after 2, 4, and 24 hours of incubation.

Figure 4 displays fluorescent micrographs of picodroplets that contain either non-expressing control cells (top row) or PC3-LN3-PSMA target cells (bottom row) and were imaged at 2, 4, and 24 hours (left to right).

The picodroplets that contain PC3-LN3 control cells show minimal Granzyme B activity after 2 to 4 hours. However, multiple fluorescent picodroplets in the picodroplets containing PC3-LN3-PSMA cells are indicative of Granzyme B being released by the CAR-T cells in response to the target cells.

Increased fluorescence is only observed in the negative control after 24 hours of incubation, which may be attributed to either unspecific stimulation or Granzyme B leakage from dead or apoptotic CAR-T cells.

Demonstrating how to verify CAR-T cell function in microfluidic picodroplets

Figure 4. Granzyme B assay in picodroplets with co-encapsulated CAR-T and target cells (bottom) or control cells (top). Fluorescence micrographs of picodroplets after 2, 4, and 24 h (left to right). Scale bar: 100 μm. Image Credit: Sphere Fluidics

Demonstrating how to verify CAR-T cell function in microfluidic picodroplets

Figure 5. Detection of Granzyme B activity in picodroplets with Cyto-Mine®. Screenshots of Cyto-Mine® software during detection/ sorting, showing scatterplot of picodroplet size (Intra picodroplet, ms) against Fluorescence signal (Green Average, V) at t=0 (A), 1h (B) and 2h (C). The middle and bottom panel also show polygon gates used for determining percentage of positive picodroplets and for sorting. Image Credit: Sphere Fluidics

Demonstrating how to verify CAR-T cell function in microfluidic picodroplets

Figure 6. Brightfield (A) and fluorescent micrograph (B) of sorted picodroplets in dispensing chamber. Scale bar 100 μm. Image Credit: Sphere Fluidics

Demonstrating how to verify CAR-T cell function in microfluidic picodroplets

Figure 7. Cyto-Mine® - Sphere Fluidics’ automated and fully integrated single cell analysis system. Image Credit: Sphere Fluidics

Download the full paper

About Sphere Fluidicslogo

Our vision

Our philosophy is simple. We combine our knowledge and resources to help you find rare and valuable biological variants, while helping you to save time, reduce costs and stay a step ahead of the competition.

Our novel single cell analysis systems offer the rapid screening and characterization of single cells. These systems are underpinned by our patented picodroplet technology, specifically designed to increase your chances of finding that rare ‘one-in-a-billion’ molecule or cell that could be an industry blockbuster.

We understand that time is of the essence. That’s why our technologies boost throughput and assay sensitivity across a range of applications. Most importantly, our flexible systems evolve alongside your changing research needs, providing an adaptable platform that helps you to meet your goals.

Our history

Founded in 2010, Sphere Fluidics is an established Life Sciences company, originally spun out from the University of Cambridge. We initially developed 25 patented products – biochips and specialist chemicals – which currently assist hundreds of customers globally with their research.

We initially focused on producing novel biochip systems and providing R&D services. We have since extended our expertise and are developing a technology platform that enables discovery in a range of growing markets through single cell analysis. Our systems make the development of new biopharmaceuticals faster and more cost-effective, improve monoclonal antibody screening, cell line development, and overall research efficiency in a number of other applications including synthetic biology, single cell diagnostics, prognostics and single cell genome editing.

The Cyto-Mine® Single Cell Analysis System is our flagship product – the first integrated, benchtop system to automatically analyse, sort and dispense millions of individual cells in just a single day.

Our partnerships

We value and are always open to discussing new collaborative, successful and innovative academic and industry partnerships to further develop and improve our single cell technologies.

Our Technology Access Programmes and Collaborative Services exist to enable academic researchers and companies alike to tap into our application-specific expertise through direct partnerships.

Sponsored Content Policy: publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Apr 10, 2024 at 5:28 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sphere Fluidics. (2024, April 10). Demonstrating how to verify CAR-T cell function in microfluidic picodroplets. News-Medical. Retrieved on April 21, 2024 from

  • MLA

    Sphere Fluidics. "Demonstrating how to verify CAR-T cell function in microfluidic picodroplets". News-Medical. 21 April 2024. <>.

  • Chicago

    Sphere Fluidics. "Demonstrating how to verify CAR-T cell function in microfluidic picodroplets". News-Medical. (accessed April 21, 2024).

  • Harvard

    Sphere Fluidics. 2024. Demonstrating how to verify CAR-T cell function in microfluidic picodroplets. News-Medical, viewed 21 April 2024,

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.